Hypothermia in Children After Trauma
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary hypothesis for this application for a multicenter phase III randomized clinical trial (RCT) is that induced moderate hypothermia (HYPO) (32-33 °C) after severe traumatic brain injury (TBI) in children and maintained for 48 hours will improve mortality at 3 months and 12 month functional outcome as assessed by the Glasgow Outcome Scale (GOS).
| Condition | Intervention | Phase |
|---|---|---|
|
Traumatic Brain Injury |
Procedure: induced moderate hypothermia |
Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Pediatric Traumatic Brain Injury Consortium: Hypothermia |
- The primary specific aim of this RCT is to determine the effect of induced moderate HYPO (32-33 °C) after severe TBI in children on mortality. [ Time Frame: 3 month post injury ] [ Designated as safety issue: No ]
- To determine the effect of HYPO after severe TBI in children on global function and neurocognitive outcomes in the areas of intellectual ability/development, memory and learning, and behavior. [ Time Frame: at 6 and 12 months post injury ] [ Designated as safety issue: No ]
- To determine the effect of HYPO after severe TBI in children of different age ranges (< 6y; 6-<16y; and 16-<18y) on mortality and 6 and 12 months functional and neurocognitive outcomes. [ Time Frame: 3, 6 and 12 months post injury ] [ Designated as safety issue: No ]
- To determine the effect of HYPO after severe TBI in children on reducing intracranial hypertension and maintaining adequate cerebral perfusion pressure (CPP). [ Time Frame: 7 days post injury ] [ Designated as safety issue: No ]
| Enrollment: | 90 |
| Study Start Date: | November 2007 |
| Study Completion Date: | March 2012 |
| Primary Completion Date: | May 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: A
Induced moderate hypothermia (32-33 C)
|
Procedure: induced moderate hypothermia
Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
|
Detailed Description:
The primary specific aim of this RCT is to determine the effect of induced moderate HYPO (32-33 °C) after severe TBI in children on mortality at 3 months post injury. The primary outcome measure will be the GOS; the primary time point for evaluation is 3 months. Further secondary functional outcome measures will include the GOS - Extended Pediatrics (GOS - E Peds), and Vineland Adaptive Behavior Scale (VABS) and will be assessed in conjunction with the GOS at 6 and 12 months post injury.
The secondary hypotheses are based on the results and analysis of the Pilot Clinical Trial (completed and recently published [Adelson et al. NEUROSURGERY. 56 (4): 740-754, 2005]). These secondary hypotheses include that induced moderate hypothermia (HYPO) (32-33 °C) after severe TBI in children and maintained for 48 h:
- will improve other outcome assessments including neurocognitive status on performance-based neuropsychological testing across the domains of intellectual development, learning and memory, language, motor and psychomotor skills, visuo-spatial abilities, attention and executive function, and behavior at only 6 and 12 months after injury;
- HYPO will improve long term outcome of all age ranges and across genders in infants, young, preadolescent, and adolescent children; AND
- HYPO will lessen intracranial hypertension and lessen the intensity of therapy necessary for control of ICP.
Based on these hypotheses, further secondary specific aims are proposed:
- Specific Aim 2: To determine the effect of early induced moderate HYPO (32-33°C) after severe TBI in children on global function and neurocognitive outcomes in the areas of intellectual ability/ development, memory and learning, and behavior at 6 and 12 months post injury.
- Specific Aim 3: To determine the effect of early induced moderate HYPO after severe TBI in children of different age ranges (< 6 y and 6- < 16 y) on mortality and 6 and 12 months functional and neurocognitive outcomes.
- Specific Aim 4: To determine the effect of early moderate HYPO after severe TBI in children on reducing intracranial hypertension and maintaining adequate cerebral perfusion pressure (CPP).
Eligibility| Ages Eligible for Study: | up to 17 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with a GCS </= 8
- Glasgow Motor Score < 6
- Closed head injury
- Age 0 < 18 y
Exclusion Criteria
- Unavailable to initiate cooling within 6 hours of injury
- Glasgow Coma Scale (GCS) score = 3 and abnormal brainstem function
- Normal initial CT scan (No blood, fracture, swelling, and/or shift)
- Penetrating brain injury
- No known mechanism of injury
- Unknown time of injury
- Uncorrectable coagulopathy (PT/PTT > 16/40 sec, INR > 1.7)
- Hypotensive episode (Systolic Blood Pressure <5th percentile for age>10 min)
- Documented Hypoxic episode (O2 saturation < 94% for > 30 min)
- Pregnancy
Contacts and Locations
Show 30 Study Locations| Principal Investigator: | P. David Adelson, MD | Phoenix Children's Hospital |
More Information
No publications provided
| Responsible Party: | Phoenix Children's Hospital |
| ClinicalTrials.gov Identifier: | NCT00222742 History of Changes |
| Other Study ID Numbers: | 1R01-NS052478-01, 1R01NS052478-01 |
| Study First Received: | September 16, 2005 |
| Last Updated: | July 10, 2012 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Phoenix Children's Hospital:
|
hypothermia pediatric TBI |
Additional relevant MeSH terms:
|
Hypothermia Brain Injuries Body Temperature Changes Signs and Symptoms Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Craniocerebral Trauma Trauma, Nervous System Wounds and Injuries |
ClinicalTrials.gov processed this record on May 22, 2013